<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6156">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01051817</url>
  </required_header>
  <id_info>
    <org_study_id>CAIN457B2201</org_study_id>
    <secondary_id>2009-011626-34</secondary_id>
    <nct_id>NCT01051817</nct_id>
  </id_info>
  <brief_title>POC-MD MRI-based Trial in Relapsing-remitting Multiple Scler</brief_title>
  <official_title>A Randomized, Multi-center, Double-blind, Proof-of-concept Study to Assess the Effect of Multiple Infusion of AIN457 (10 mg/kg) Versus Placebo on Disease Activity as Measured by MRI Scans Over a 24 Week Period in Patients With Relapsing-remitting Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, multi-center, double-blind, proof-of-concept study to assess the effect of
      multiple infusions of AIN457 (10 mg/kg) versus placebo on disease activity as measured by
      MRI scans over a 24 week period in patients with relapsing-remitting multiple sclerosis
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Summary of Raw Number of Cumulative Combined Unique Active Lesions in Patients With Relapsing Remitting Multiple Sclerosis by Visit and Treatment</measure>
    <time_frame>weeks 4,8,12,16,20,24,28</time_frame>
    <safety_issue>No</safety_issue>
    <description>Combined unique active lesions (CUAL) observed on brain MRI scans performed every 4th week from week 4 to week 24 in patients with relapsing-remitting multiple sclerosis (RRMS). CUAL is defined as: new gadolinium (Gd)-enhancing lesions on T1-weighted, or new or enlarging lesions on T2-weighted MRI scans, without double counting.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Raw Number of Cumulative New Gd-T1 Lesions</measure>
    <time_frame>MRI brain scans performed every 4 weeks at week 4, 8, 12, 16, 20, 24 and 28 (EOS).</time_frame>
    <safety_issue>No</safety_issue>
    <description>The summary of raw number of cumulative new Gadolinium-enhanced T1 lesions observed on brain MRI scans performed every 4th week from WK 4 to WK 28. The end-point is week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Raw Number of Cumulative New Gd-T2 Lesions</measure>
    <time_frame>MRI brain scans performed every 4 weeks at week 4, 8, 12, 16, 20, 24 and 28 (EOS).</time_frame>
    <safety_issue>No</safety_issue>
    <description>The summary of raw number of cumulative new Gadolinium-enhanced T2 lesions observed on brain MRI scans performed every 4th week from WK 4 to WK 28. The endpoint is week 24.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Relapsing-remitting Multiple Sclerosis</condition>
  <condition>RRMS</condition>
  <arm_group>
    <arm_group_label>AIN457</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AIN457</intervention_name>
    <description>infusion 10 mg/Kg</description>
    <arm_group_label>AIN457</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ostrava-Moravska Ostrava</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ostrava</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha 10</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha 2</city>
        <zip>128 08</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Teplice</city>
        <zip>415 29</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kazan</city>
        <zip>420021</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>129128</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603155</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Smolensk</city>
        <zip>214019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kharkiv</city>
        <zip>61068</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kiev</city>
        <zip>03110</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Odessa</city>
        <zip>65025</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vinnitsya</city>
        <zip>21005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
  </location_countries>
  <removed_countries>
    <country>Serbia</country>
    <country>Sweden</country>
  </removed_countries>
  <verification_date>February 2015</verification_date>
  <lastchanged_date>February 12, 2015</lastchanged_date>
  <firstreceived_date>January 19, 2010</firstreceived_date>
  <firstreceived_results_date>February 12, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>relapsing-remitting multiple sclerosis</keyword>
  <keyword>RRMS</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>AIN457</title>
          <description>IV dose 10 mg/kg week 0, 2, 4, 8, 12, 16, and 20.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo IV week 0, 2, 4, 8, 12, 16, and 20.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal Test Proceedure reults</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AIN457</title>
          <description>IV dose 10 mg/kg week 0, 2, 4, 8, 12, 16, and 20.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo IV week 0, 2, 4, 8, 12, 16, and 20.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="38"/>
                <measurement group_id="B2" value="35"/>
                <measurement group_id="B3" value="73"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="36.1" spread="9.8"/>
                <measurement group_id="B2" value="32.7" spread="9.9"/>
                <measurement group_id="B3" value="34.5" spread="9.95"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="21"/>
                <measurement group_id="B2" value="29"/>
                <measurement group_id="B3" value="50"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="17"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="23"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="4"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Not Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="35"/>
                <measurement group_id="B2" value="34"/>
                <measurement group_id="B3" value="69"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>American Indian or Alaska Native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or Other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="36"/>
                <measurement group_id="B2" value="33"/>
                <measurement group_id="B3" value="69"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>More than one race</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="4"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Summary of Raw Number of Cumulative Combined Unique Active Lesions in Patients With Relapsing Remitting Multiple Sclerosis by Visit and Treatment</title>
        <description>Combined unique active lesions (CUAL) observed on brain MRI scans performed every 4th week from week 4 to week 24 in patients with relapsing-remitting multiple sclerosis (RRMS). CUAL is defined as: new gadolinium (Gd)-enhancing lesions on T1-weighted, or new or enlarging lesions on T2-weighted MRI scans, without double counting.</description>
        <time_frame>weeks 4,8,12,16,20,24,28</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457B</title>
            <description>10 mg/Kg IV week 0, 2, 4, 8, 12, 16, and 20</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo IV week 0, 2, 4, 8, 12, 16, and 20.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="38"/>
                  <measurement group_id="O2" value="35"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Summary of Raw Number of Cumulative Combined Unique Active Lesions in Patients With Relapsing Remitting Multiple Sclerosis by Visit and Treatment</title>
            <description>Combined unique active lesions (CUAL) observed on brain MRI scans performed every 4th week from week 4 to week 24 in patients with relapsing-remitting multiple sclerosis (RRMS). CUAL is defined as: new gadolinium (Gd)-enhancing lesions on T1-weighted, or new or enlarging lesions on T2-weighted MRI scans, without double counting.</description>
            <units>Combined Unique Active Lesions</units>
            <param>Mean</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <sub_title>Week 4 (n=37,34)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.4" lower_limit="0" upper_limit="33"/>
                  <measurement group_id="O2" value="3.2" lower_limit="0" upper_limit="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 8 (n=36, 31)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.9" lower_limit="0" upper_limit="47"/>
                  <measurement group_id="O2" value="5.4" lower_limit="0" upper_limit="27"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 12 (n=35,31)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.4" lower_limit="0" upper_limit="80"/>
                  <measurement group_id="O2" value="8.6" lower_limit="0" upper_limit="34"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 16 (n=32,29)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6.0" lower_limit="0" upper_limit="104"/>
                  <measurement group_id="O2" value="11.5" lower_limit="0" upper_limit="50"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 20 (n=34,27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.7" lower_limit="0" upper_limit="118"/>
                  <measurement group_id="O2" value="13.0" lower_limit="0" upper_limit="51"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 24 (n=32,24)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.7" lower_limit="0" upper_limit="122"/>
                  <measurement group_id="O2" value="15.1" lower_limit="0" upper_limit="64"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 28 (n=32,29)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9.4" lower_limit="0" upper_limit="142"/>
                  <measurement group_id="O2" value="19.9" lower_limit="0" upper_limit="110"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Raw Number of Cumulative New Gd-T1 Lesions</title>
        <description>The summary of raw number of cumulative new Gadolinium-enhanced T1 lesions observed on brain MRI scans performed every 4th week from WK 4 to WK 28. The end-point is week 24.</description>
        <time_frame>MRI brain scans performed every 4 weeks at week 4, 8, 12, 16, 20, 24 and 28 (EOS).</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457B</title>
            <description>10 mg/Kg IV week 0, 2, 4, 8, 12, 16, and 20</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo IV week 0, 2, 4, 8, 12, 16, and 20.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="38"/>
                  <measurement group_id="O2" value="35"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Raw Number of Cumulative New Gd-T1 Lesions</title>
            <description>The summary of raw number of cumulative new Gadolinium-enhanced T1 lesions observed on brain MRI scans performed every 4th week from WK 4 to WK 28. The end-point is week 24.</description>
            <units>cumulative new Gd-T1 lesions</units>
            <param>Mean</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <sub_title>Week 4 (n=37,34)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.4" lower_limit="0" upper_limit="31"/>
                  <measurement group_id="O2" value="1.7" lower_limit="0" upper_limit="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 8 (n= 36,31)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.6" lower_limit="0" upper_limit="44"/>
                  <measurement group_id="O2" value="3.0" lower_limit="0" upper_limit="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 12 (n=35,31)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.3" lower_limit="0" upper_limit="76"/>
                  <measurement group_id="O2" value="5.5" lower_limit="0" upper_limit="26"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 16 (n= 32,29)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.0" lower_limit="0" upper_limit="99"/>
                  <measurement group_id="O2" value="7.8" lower_limit="0" upper_limit="36"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 20 (n=34,27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.6" lower_limit="0" upper_limit="112"/>
                  <measurement group_id="O2" value="9.2" lower_limit="0" upper_limit="40"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 24 (n=32,24)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.4" lower_limit="0" upper_limit="116"/>
                  <measurement group_id="O2" value="11.1" lower_limit="0" upper_limit="55"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 28 (n=32,29)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6.5" lower_limit="0" upper_limit="135"/>
                  <measurement group_id="O2" value="14.4" lower_limit="0" upper_limit="99"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Raw Number of Cumulative New Gd-T2 Lesions</title>
        <description>The summary of raw number of cumulative new Gadolinium-enhanced T2 lesions observed on brain MRI scans performed every 4th week from WK 4 to WK 28. The endpoint is week 24.</description>
        <time_frame>MRI brain scans performed every 4 weeks at week 4, 8, 12, 16, 20, 24 and 28 (EOS).</time_frame>
        <safety_issue>No</safety_issue>
        <population>full analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457B</title>
            <description>10 mg/Kg IV week 0, 2, 4, 8, 12, 16, and 20</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo IV week 0, 2, 4, 8, 12, 16, and 20.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="38"/>
                  <measurement group_id="O2" value="35"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Raw Number of Cumulative New Gd-T2 Lesions</title>
            <description>The summary of raw number of cumulative new Gadolinium-enhanced T2 lesions observed on brain MRI scans performed every 4th week from WK 4 to WK 28. The endpoint is week 24.</description>
            <units>Cumulative new Gd-T2 lesions</units>
            <param>Mean</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <sub_title>Week 4 (n= 37,34)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.3" lower_limit="0" upper_limit="30"/>
                  <measurement group_id="O2" value="3.1" lower_limit="0" upper_limit="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 8 (n=36,31)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.6" lower_limit="0" upper_limit="43"/>
                  <measurement group_id="O2" value="5.4" lower_limit="0" upper_limit="28"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 12 (n=35,31)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.0" lower_limit="0" upper_limit="72"/>
                  <measurement group_id="O2" value="8.3" lower_limit="0" upper_limit="34"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 16 (n=32,29)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.6" lower_limit="0" upper_limit="91"/>
                  <measurement group_id="O2" value="11.0" lower_limit="0" upper_limit="50"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 20 (n= 34,27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.2" lower_limit="0" upper_limit="106"/>
                  <measurement group_id="O2" value="12.3" lower_limit="0" upper_limit="51"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 24 (n=32,24)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.2" lower_limit="0" upper_limit="110"/>
                  <measurement group_id="O2" value="14.6" lower_limit="0" upper_limit="64"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 28 (n=32,29)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8.8" lower_limit="0" upper_limit="126"/>
                  <measurement group_id="O2" value="19.1" lower_limit="0" upper_limit="110"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>PLACEBO</title>
          <description>PLACEBO</description>
        </group>
        <group group_id="E2">
          <title>AIN457 10mg/kg</title>
          <description>AIN457 10mg/kg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
